Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount ⊖
found
a story from CNBC ⚠️ › World News
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.